AmCAD-UV
AmCad BioMed Corporation • Radiology • 04/26/2017
Device Purpose
AmCAD-UV is a software device designed for vascular pulsatility analysis by classifying ultrasonic color intensity data from flow Doppler ultrasound images, allowing users to view color-coded signals and waveform trends. Its methodology involves quantifying color pixels based on intensity, grouping those with similar periodic pulsatile waveforms, and generating visualizations to aid in evaluating parameters like flow velocity and energy, though not for standalone diagnostic interpretation.
Summary
AmCAD-UV is a software medical device designed to assist in vascular pulsatility analysis by processing flow Doppler ultrasound images. Its core function is to classify ultrasonic color intensity data obtained from these images. The software quantifies color pixels within a user-defined scanning area based on their color intensities and then groups pixels exhibiting similar periodic pulsatile waveforms. This process results in the generation of an image displaying classified color-coded signals, which are categorized as primary pulsatile, secondary pulsatile, and unidentified signals. The device aims to provide clinicians with a tool to better evaluate vascular pulsatility, such as pulsatile flow velocity and flow energy, depending on the type of flow Doppler image being analyzed. The AmCAD-UV system operates as a Picture Archiving and Communication System (PACS) tool, meaning it does not generate new quantitative measurements but rather provides enhanced visualization and analysis of existing information from flow Doppler ultrasound images. It offers a dual-image display, showing both the original ultrasound image and the processed image with classified color-coded signals. Users can delineate a specific region of interest (ROI) for targeted analysis. Furthermore, the software provides a trend chart that displays pulsatile waveforms alongside summarized statistical data. AmCAD-UV allows for the export of quantified values of the classified pulsatile signals in text format, and the sequence of color-coded images and waveform trend charts can be exported in standard image formats like Bitmap and JPEG. It is emphasized that this tool is intended for general-purpose medical image processing and must not be used as the sole basis for primary diagnostic interpretation.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the AmCAD-UV algorithm differentiate between 'primary pulsatile,' 'secondary pulsatile,' and 'unidentified' signals, and what are the specific criteria or thresholds used for this classification?; What is the clinical significance or diagnostic implication of distinguishing 'secondary pulsatile' signals from 'primary pulsatile' signals in vascular pulsatility analysis?; How does the software handle variations in ultrasound image quality or artifacts (e.g., aliasing, motion) when classifying color intensity data and generating pulsatile waveforms?; What specific quantitative metrics, beyond visual classification and trend charts (e.g., pulsatility index, resistance index from the waveforms), can be derived using AmCAD-UV to assess vascular health?; Has the performance of AmCAD-UV in classifying pulsatile signals been validated against established quantitative Doppler methods or in specific vascular beds or disease states?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly